kairoby Opportune Labs

Zn-Thymulin

Zinc-thymulin combines a thymic peptide with zinc. It has been studied in immune biology and explored as a topical approach to androgenetic hair loss.

Investigational / researchPreclinical biology; small exploratory hair report
Kairo editorial · Sources reviewed September 9, 20264 sources
On this page
  1. Overview
  2. What the evidence shows
  3. Safety
  4. Common questions
  5. Questions for your clinician
  6. Sources

This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.

Overview

Product & regulatory status

The evidence is preliminary and should not be described as an established hair-restoration treatment.

Zinc-dependent biology

The experimental work concerns thymulin in its zinc-associated form and immune signaling. That mechanism should not be repackaged as direct proof that it stimulates hair follicles in people. [1]

What the evidence shows

Immune-system experiments

A study examined thymic epithelial cells and immune responses in mice. It supports biological activity of the zinc-peptide complex, but it did not test treatment of human hair loss. [1]

Exploratory topical report

An uncontrolled report followed 18 adults. Overall visual improvement was not statistically significant; a subgroup treated longer showed improvement. Some participants also used other hair treatments, and the author disclosed financial interests. These limitations make the result exploratory. [2]

What remains unknown

Independent controlled hair trials, durability of any benefit, and long-term local or systemic effects remain unresolved.

Safety

Limited safety observation

The topical report describes tolerability during its observation period. That cannot establish safety for injections, different preparations, broad populations, or prolonged use. [2]

Route-specific evidence

The hair report concerns topical application. The findings should remain attached to that preparation and route rather than generalized to every product with the same name. [2]

Understanding product quality

Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]

When to seek urgent help

Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]

A starting point for discussion

This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.

Common questions

Is this the same as correcting a zinc deficiency?

No. Research on a zinc-bound peptide is not equivalent to evidence about ordinary dietary zinc replacement.

Questions for your clinician

Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?

Sources

  1. Zinc-thymulin in cell and mouse immune experiments1995 · Original research · PubMed
  2. Topical zinc-thymulin in androgenetic alopeciaVickers · 2017 · Small uncontrolled clinical report
  3. Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
  4. AnaphylaxisMedlinePlus · recognizing an emergency

Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.